Abstract:Simple Summary Anti-angiogenesis agents have shown anti-cancer activity by preventing blood vessel ingrowth, thereby limiting tumour growth and metastasis. Although these molecules lead to prolonged overall survival of cancer patients, therapy resistance is easily acquired. Therefore, novel inhibitors against other signaling pathways mediating angiogenesis are needed to achieve more efficient and sustainable targeting of the angiogenesis process. Here, we synthesized and identified two compounds belonging to a new class of small molecules termed macrocyclics that selectively inhibit bone morphogenetic protein receptor kinase activity. One compound also inhibits vascular endothelial growth factor-induced signalling. Treatment studies using in vitro cultured cells and zebrafish embryos revealed that both compounds impaired endothelial cell function and decreased normal and tumour-induced angiogenesis. Both compounds might provide a steppingstone for the development of novel-angiogenesis therapeutic agents. Angiogenesis, i.e., the formation of new blood vessels from pre-existing endothelial cell (EC)-lined vessels, is critical for tissue development and also contributes to neovascularization-related diseases, such as cancer. Vascular endothelial growth factor (VEGF) and bone morphogenetic proteins (BMPs) are among many secreted cytokines that regulate EC function. While several pharmacological anti-angiogenic agents have reached the clinic, further improvement is needed to increase clinical efficacy and to overcome acquired therapy resistance. More insights into the functional consequences of targeting specific pathways that modulate blood vessel formation may lead to new therapeutic approaches. Here, we synthesized and identified two macrocyclic small molecular compounds termed OD16 and OD29 that inhibit BMP type I receptor (BMPRI)-induced SMAD1/5 phosphorylation and downstream gene expression in ECs. Of note, OD16 and OD29 demonstrated higher specificity against BMPRI activin receptor-like kinase 1/2 (ALK1/2) than the commonly used small molecule BMPRI kinase inhibitor LDN-193189. OD29, but not OD16, also potently inhibited VEGF-induced extracellular regulated kinase MAP kinase phosphorylation in ECs. In vitro, OD16 and OD29 exerted strong inhibition of BMP9 and VEGF-induced ECs migration, invasion and cord formation. Using Tg (fli:EGFP) zebrafish embryos, we found that OD16 and OD29 potently antagonized dorsal longitudinal anastomotic vessel (DLAV), intra segmental vessel (ISV), and subintestinal vessel (SIV) formation during embryonic development. Moreover, the MDA-MB-231 breast cancer cell-induced tumor angiogenesis in zebrafish embryos was significantly decreased by OD16 and OD29. Both macrocyclic compounds might provide a steppingstone for the development of novel anti-angiogenesis therapeutic agents.

Inhibition of Tumor Angiogenesis by Cell-Permeable Dominant Negative SOX18 Mutants

Inhibition of angiogenesis in cancer by iNOS antisense oligodeoxynucleotide

Inhibition of Human Hepatocellular Carcinoma Tumor Angiogenesis by Sirna Silencing of VEGF Via Hepatic Artery Perfusion.

Antiangiogenesis and Damaging Blood Flow by Antisense Vascular Endothelial Growth Factor Oligodeoxynucleotides to Suppress Lung Cancers

Enhancing tumor radiosensitivity by intracellular delivery of survivin antagonists.

Single or Double Transfection of Angiostatin and Endostatin Genes Affect Mammary Tumor Growth, Lung Metastasis and Structural and Perfused Vessels

The Inhibition of Protein Translation Promotes Tumor Angiogenic Switch.

Antiangiogenic Activity of Recombinant Eukaryotic Expression Vectors Carrying Genes Encoding Attenuated Shiga-like Toxin Ⅰ Mutant

Lentivirus-mediated shRNA interference targeting vascular endothelial growth factor inhibits angiogenesis and progression of human pancreatic carcinoma.

A Novel Angiogenesis Inhibitor Impairs Lovo Cell Survival Via Targeting Against Human VEGFR and Its Signaling Pathway of Phosphorylation

Data from Context-Dependent Role of Angiopoietin-1 Inhibition in the Suppression of Angiogenesis and Tumor Growth: Implications for AMG 386, an Angiopoietin-1/2–Neutralizing Peptibody

Inhibiting Colorectal Carcinoma Growth and Metastasis by Blocking the Expression of Vegf Using Rna Interference

Reversine Suppresses Osteosarcoma Cell Growth Through Targeting BMP-Smad1/5/8-mediated Angiogenesis

Suppression of growth of pancreatic cancer cell and expression of vascular endothelial growth factor by gene silencing with RNA interference.

Inhibiting Endothelial Cell Function in Normal and Tumor Angiogenesis Using BMP Type I Receptor Macrocyclic Kinase Inhibitors

Sox2 Enhances Breast Tumor Angiogenesis By Promoting The Transition Of Cancer Cell To Cd31+And Lyve-1+Cells

Suppression Of Survivin Expression Inhibits In Vivo Tumorigenicity And Angiogenesis In Gastric Cancer

Inhibition of K562 Leukemia Angiogenesis and Growth by Expression of Antisense Vascular Endothelial Growth Factor (VEGF) Sequence

Cell-permeable hypoxia-inducible factor-1 (HIF-1) antagonists function as tumor radiosensitizers.

Inhibition of lymphatic metastases by a survivin dominant-negative mutant

Inhibitory Effects of Angiostatin Gene Combined with Antisense Hypoxia Inducible Factor-1Α Gene Transfection on Implanted Human Ovarian Carcinoma in Nude Mice